Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by whippeton Sep 01, 2017 1:44pm
144 Views
Post# 26648171

RE:RE:RE:SP ....

RE:RE:RE:SP ....
Tiger, i disagree, 
i would rather see management get options instead of higher paycheck.
also, this is a penny stock with revenues and strong growth potential. 
if balance sheet was so strong, it would be trading at much higher price...
so i consider this a great opportunity.
in this case, profit has less  to do with stock price. Revenues (revenues growth)  and   technology, new tech applications (cardio) and expectation of new contracts are gonna be the basis for increased price of the shares.
I also do believe that for Fiscal 2018 (March) we are gonna be profitable which would be very positive because then they would not need to raise more money, unless a big contract was signed. 
Short term,  with potential growth, technology and revenues potential, we should be trading in the .20 to .25 range.
JMO


Bullboard Posts